Citable filing context
TECH's research view summarizes recent SEC filing context, starting with earnings from Aug 12, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 12, 2026 | earnings | Bio-Techne reported fiscal 2026 fourth quarter revenue of $321.2 million and full year revenue of $1.2 billion. |
| Jun 26, 2026 | acquisition | Bio-Techne Corporation entered into an agreement to be acquired by Merck KGaA for $73.00 per share in cash. |
| Jun 25, 2026 | acquisition | Bio-Techne to be acquired by Merck KGaA for $73 per share, totaling $11.3 billion. |
| Jun 25, 2026 | Guidance: cost_synergies | not reported to 140.00 |
| May 6, 2026 | mda_quarterly | Bio-Techne reported consolidated net sales of $311.4 million for the quarter ended March 31, 2026, a 2% year-over-year decrease. Organic revenue declined 2%, driven by unfavorable volume and product mix within the Protein Sciences segment—which focuses on cytokines, antibodies, and protein analysis—partially offset by 3% organic growth in the Diagnostics and Spatial Biology portfolio. GAAP gross margins contracted to 66.9% from 67.9% due to shifting product mix. Operating margins in Protein Sciences fell to 44.2%, while Diagnostics and Spatial Biology margins improved to 12.1%, supported by the Exosome Diagnostics divestiture and profitability initiatives. The company reduced SG&A expenses by 28% to $109.3 million, citing cost management and the absence of a prior-year non-recurring arbitration award. A significant upcoming capital requirement is the mandatory acquisition of the remaining 80.1% of Wilson Wolf by December 31, 2027, estimated at $1 billion plus contingent consideration. To support this obligation and ongoing operations, Bio-Techne holds $214.1 million in cash and available-for-sale investments, complemented by an $800 million revolving credit facility. |
| Feb 4, 2026 | mda_quarterly | Bio-Techne reported flat consolidated net sales of $295.9 million for the quarter ended December 31, 2025, with organic revenue remaining stagnant. Growth in the Diagnostics and Spatial Biology portfolio was offset by unfavorable product mix within the Protein Sciences segment. Adjusted gross margins declined to 68.5% from 70.5% year-over-year, primarily due to shifting product mix. Cost management initiatives reduced quarterly SG&A and R&D expenses by 6% and 8%, respectively. While Protein Sciences' operating margin decreased to 39.3%, the Diagnostics and Spatial Biology segment's operating margin improved to 10.4%, driven by the Exosome Diagnostics divestiture and profitability initiatives. A significant upcoming capital requirement is the mandatory acquisition of the remaining 80.1% of Wilson Wolf by December 31, 2027, estimated at $1 billion plus contingent consideration. Liquidity remains stable with $172.9 million in cash and available-for-sale investments and $740 million available on its revolving credit facility. Six-month operating cash flow decreased to $110 million from $148.2 million, reflecting changes in the timing of operating asset and liability payments. The company continues to face risks related to product mix volatility, currency fluctuations, and the integration of newly acquired businesses. |
| Nov 5, 2025 | mda_quarterly | Bio-Techne reported consolidated net sales of $286.6 million for the quarter ended September 30, 2025, a 1% year-over-year decrease. Organic revenue declined 1%, as volume pressure in the Protein Sciences segment—which provides cytokines, antibodies, and ELISA workflows—offset 3% organic growth in the Diagnostics and Spatial Biology segment. The Diagnostics segment, focusing on oncology assays and in-situ hybridization, improved its operating margin to 11.2% from 5.1%, driven by productivity initiatives and the Exosome Diagnostics divestiture. Adjusted gross margin increased to 70.2%, while SG&A expenses fell 2% due to cost management. R&D expenses rose 2% to $24.2 million to support strategic growth investments. A critical future capital commitment involves the mandatory acquisition of the remaining 80.1% of Wilson Wolf by December 31, 2027, with an estimated payment of $1 billion plus contingent consideration expected between fiscal 2026 and 2028. The company holds $145 million in cash and has $700 million available on its revolving credit facility. Operating cash flow decreased to $27.6 million from $63.9 million in the prior year, primarily due to the timing of payments on operating assets and liabilities. |
Source: SEC EDGAR filing text and events; period Aug 12, 2026; filed Aug 12, 2026.
TECH company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.